TELA Bio Inc

For the period ended Dec 31, 2023. Filed Mar 22, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 22, 2024

TELA$0.86+5.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	TELA BIO, INC.

	By:	/s/ ANTONY KOBLISH
		Name: Antony Koblish
		Title: President, Chief Executive Officer and DirectorDate: March 22, 2024

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature	Title	Date

/s/ ANTONY KOBLISH	President, Chief Executive Officer and Director (Principal Executive Officer)	March 22, 2024
Antony Koblish

/s/ ROBERTO CUCA	Chief Operating Officer and Chief Financial Officer(Principal Financial Officer)	March 22, 2024
Roberto Cuca

/s/ MEGAN SMEYKAL	Chief Accounting Officer and Controller (Principal Accounting Officer)	March 22, 2024
Megan Smeykal

/s/ DOUG EVANS	Chairman, Board of Directors	March 22, 2024
Doug Evans

/s/ KURT AZARBARZIN	Director	March 22, 2024
Kurt Azarbarzin

/s/ VINCE BURGESS	Director	March 22, 2024
Vince Burgess

/s/ LISA COLLERAN	Director	March 22, 2024
Lisa Colleran

/s/ FEDERICA O’BRIEN	Director	March 22, 2024
Federica O’Brien

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.